Where does Del Mar Pharmaceuticals (BC) Limited rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Del Mar Pharmaceuticals (BC) Limited ranks #31,378 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Del Mar Pharmaceuticals (BC) Limited hold?

Del Mar Pharmaceuticals (BC) Limited holds 8 US utility patents granted between 2018 and 2023, spanning 9 technology areas.

What is Del Mar Pharmaceuticals (BC) Limited's Innovation Score?

Del Mar Pharmaceuticals (BC) Limited has an Innovation Score of 36.9 out of 100 (top 45% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Del Mar Pharmaceuticals (BC) Limited focus on?

Del Mar Pharmaceuticals (BC) Limited's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 6 patents, ranking #2,984 of 6,058 assignees active in that subclass. Grants appear in 9 CPC subclasses total.

Is Del Mar Pharmaceuticals (BC) Limited's patent grant rate increasing or decreasing?

Del Mar Pharmaceuticals (BC) Limited's recent grant velocity is +200% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Del Mar Pharmaceuticals (BC) Limited's patents?

Del Mar Pharmaceuticals (BC) Limited's patents average 16.4 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Del Mar Pharmaceuticals (BC) Limited patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Del Mar Pharmaceuticals (BC) Limited

USPTO PatentsView assignee record - 8 granted patents across 9 technology areas, recorded in grant years 2018–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Del ranks #31,378 of 49,997 tracked US assignees by granted-patent volume, with 8 patents across 9 technology areas.

#31,378
of 49,997 US assignees by volume: Top 45%
by Innovation Score (36.9/100): 16.4
avg claims per patent: +200%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R31378 · Foreign Corporation #31,378 · 8 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 8 grants
MID-PACK #31,378/49,997
PHOTO-FINISH Davian Enterprises
CPC-NARROW A61P · 9 areas
INNOV-THIN 36.9/100
CLAIMS-RICH 16.4 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-SURGE +200% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Davian Enterprises, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Del’s 36.9 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 7.6 pts (21%) Velocity 8.9 pts (24%) Breadth 10.6 pts (29%) Claim depth 9.8 pts (27%)

Qualcomm Incorporated · highest

85
Del Mar Pharmaceutic… · this assignee

37
3D Lighting… · lowest

7

What this shows Del's Innovation Score is 36.9/100 (top 45% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Del?

Each dot is one of Del’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Del’s own 16.4 claims/patent is at or below the 17.9 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Del vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Del's grants concentrate

Del Mar Pharmaceuticals (BC) Limited is a focused PatentsView assignee: 9 CPC subclasses with 75% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2022 (2 grants) versus a trough of 1 in 2018. By volume, Del sits between Davian Enterprises, LLC and Depixus.

Del's three-year grant acceleration

Del Mar Pharmaceuticals (BC) Limited shows 4 grants in 2022–2024 against only 3 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Davian Enterprises

8
Delorean

8
Deco Lav

8
Defenshield

8
Delca

8
Delcam

8
Deltran Operation…

8
Depixus

8
Del Mar Pharmaceu… ◀

8

What this shows Del holds 8 patents at rank #31,435, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Del

By rank, the assignees closest to #31,435 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Del's primary technology class.

Del's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

37 Top 45% higher than 55% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2018–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.

View data table

Del Mar Pharmaceuticals (BC) Limited patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2018	1	12.5%
2019	1	12.5%
2020	1	12.5%
2021	1	12.5%
2022	2	25.0%
2023	2	25.0%

Which technologies does Del Mar Pharmaceuticals (BC) Limited patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 6

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 6

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 3

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 3

Y02A - Technologies FOR Adaptation TO Climate Change 2

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 2

Y10T - Technical Subjects Covered BY Former US Classification 1

C07D - Heterocyclic Compounds 1

B01D - Separation 1

Top 9 of 9 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Del Mar Pharmaceuticals (BC) Limited's patent record in context - here's where to go next.

Del Mar Pharmaceuticals (BC) Limited's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 75% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #31,378 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Del Mar Pharmaceuticals (BC) Limited against Davian Enterprises, LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 36.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.